Skip to Main Content

Paper Details

<i>NRG1</i> Fusions in <i>KRAS</i> Wild-Type Pancreatic Cancer.
Cancer Discov
155
2018
ERBB, ERBB receptor, KRAS, KRAS wild-type (KRASWT) tumors, KRASWT, KRASwt, NRG1, NRG1 Fusions, NRG1 fusions, NRG1-rearranged tumors, PDAC, gene fusions, malignancy, oncogenic fusion genes, pancreatic ductal adenocarcinoma, patients, tumors, tyrosine, tyrosine kinase
Author NameAffiliation
Peter HorakNational Center for Tumor Diseases (NCT) Heidelberg and DKFZ
Peter HorakHeidelberg University Hospital
Peter Horak
Sebastian Uhrig
Sebastian Uhrig
Sebastian UhrigHeidelberg University
Barbara Hutter
Barbara Hutter
Barbara Hutter
Barbara Hutter
Volker Endris
Volker EndrisInstitute of Pathology, Heidelberg University Hospital
Kortine Kleinheinz
Kortine KleinheinzInstitute for Pharmacy and Molecular Biotechnology and BioQuant, Heidelberg University
Matthias Schlesner
Matthias Schlesner
Lars Feuerbach
Lars Feuerbach
Christof von KalleNational Center for Tumor Diseases (NCT) Heidelberg and DKFZ
Christof von KalleHeidelberg University Hospital
Christof von Kalle
Christof von KalleDKFZ-Heidelberg Center for Personalized Oncology (HIPO)
Albrecht Stenzinger
Albrecht StenzingerInstitute of Pathology, Heidelberg University Hospital
Benedikt Brors
Benedikt Brors
Benedikt Brors
Benedikt Brors
Stefan Fr??hlingNational Center for Tumor Diseases (NCT) Heidelberg and DKFZ
Stefan Fr??hlingHeidelberg University Hospital
Stefan Fr??hling
Stefan Fr??hling
  • 1 - 32

Datasets

Release 1.2